# 🧬 Bio-Trial Auditor

**Built for the 2026 Buildathon**

## The Problem

As of January 2026, the FDA and EMA jointly released the **"Guiding Principles of Good AI Practice in Drug Development,"** establishing a zero-tolerance regime for unverified AI data in regulatory submissions. While AI accelerates clinical research writing, it creates an **accountability crisis** — there is no reliable way to prove that a human expert verified every AI-generated data point before it enters a GxP record.

Without an immutable audit trail, organizations face:

- **$10.93 million** average cost of a healthcare data breach (2025)
- **50% increase** in FDA warning letters in FY2025
- **40% of AI projects** projected to fail by 2027 without Human-in-the-Loop validation
- **42% of researcher time** consumed by manual cross-referencing and technical debt

## The Solution

Bio-Trial Auditor acts as the **"Black Box" for clinical trials** — recording not just what the AI generated, but the human verification of that output, creating a 21 CFR Part 11-compliant chain of trust.

### How It Works

1. **AI Drafting** — A generative AI summarizes complex patient outcomes or adverse event data
2. **Audit Trigger** — The system flags every claim, number, and citation the AI generated
3. **Human Verification** — A human expert reviews each flag and links it to a source document (e.g., raw lab results)
4. **Chain of Trust Report** — Generates an immutable audit trail: *AI Output → Source Document → Human Approver*

### Key Features

- **Split-View Interface** — AI-generated report on one side, Evidence Vault (source documents) on the other
- **Tiered Verification System** — Tier 1 (auto-check), Tier 2 (single human), Tier 3 (double-blind verification for high-stakes data like adverse events)
- **Append-Only Audit Ledger** — Database records can never be edited or deleted, only appended
- **Conflict Resolution** — When AI output contradicts source data, the system forces a human override with documented justification
- **Compliance Heartbeat** — Real-time regulatory readiness monitoring

## Tech Stack

- **Frontend:** React + Vite + TypeScript + Tailwind CSS + shadcn/ui
- **Backend:** Supabase (append-only audit logs with Row Level Security)
- **Architecture:** Immutable ledger design meeting 21 CFR Part 11 requirements

## Impact

| Category | Metric |
| :--- | :--- |
| **Cost Avoidance** | Mitigates $10.93M average data breach cost |
| **Time Savings** | Reduces 42% manual cross-referencing to review-and-click |
| **Regulatory Speed** | Accelerates trial submission by ~30 days |
| **Compliance** | Built for 2026 FDA Good AI Practice guidelines |

## References

- [FDA AI for Drug Development (Jan 2026)](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development)
- [FDA/EMA Guiding Principles (Jan 2026)](https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0)
- [FDA 510(k) AI Submission Guidelines (Feb 2026)](https://intuitionlabs.ai/articles/fda-ai-510k-submission-guidelines-best-practices)
- [Global Technical Debt Report (2025)](https://www.castsoftware.com/ciu/coding-in-the-red-technical-debt-report-2025)
